If you wake up Daljeet Kohli in the middle of the night and ask him to recommend a stock, he will in all probability blurt out the name of a Pharma stock. Why? Because, Daljeet has a deep understanding of the sector and has mastered all the nuances that affect the stocks in that sector.
It is no surprise that Daljeet has attained the maximum success in his career with Pharma stocks.
In his latest report, Daljeet has carried out a careful analysis of his favourite stocks and offered clear-cut recommendations on what we should do with them.
Out of the 17 stocks listed in the report, only 7 have been awarded the coveted recommendation of “Buy”. Of these, Sharon Bio-Medicine is claimed to have the highest target gains of 90%+. This is followed by JB Chemcicals with a 28% potential gain. Aurobindo Pharma comes third with a potential of 23% gain.
A detailed explanation in support of each recommendation is given.
One stock you need to pay special attention to is IPCA Labs. When a stock picker of the caliber of Sanjoy Bhattacharyya calls it a “great chance” to buy a “wonderfully run company, with a tremendous track record and high quality management”, you know you are in safe hands. Saurabh Mukherjea, whiz-kid with Ambit Capital, echoed the same sentiments. Several other savvy experts have also recommended a buy on the stock.
So, if you haven’t already, you need to read up Daljeet’s report and carefully ponder over your next move. After all, you don’t want to miss out on a chance of making a few hefty bucks, do you.